| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1000506160 |
| P356 | DOI | 10.1038/SJ.BJC.6602108 |
| P932 | PMC publication ID | 2747688 |
| P698 | PubMed publication ID | 15305185 |
| P5875 | ResearchGate publication ID | 8406343 |
| P2093 | author name string | U Andersson | |
| M Johansson | |||
| A Bergh | |||
| A T Bergenheim | |||
| R Henriksson | |||
| M Sandström | |||
| P2860 | cites work | Endostatin: an endogenous inhibitor of angiogenesis and tumor growth | Q24315369 |
| The biology of VEGF and its receptors | Q27860704 | ||
| The Ki-67 protein: from the known and the unknown | Q28143714 | ||
| Molecular cloning of a novel vascular endothelial growth factor, VEGF-D | Q28242486 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors | Q29618610 | ||
| Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy | Q34157098 | ||
| VEGF in brain tumors | Q34178821 | ||
| Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs | Q34178829 | ||
| FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter | Q34233226 | ||
| A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. | Q34398347 | ||
| Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. | Q34693504 | ||
| Gefitinib (Iressa) trials in non-small cell lung cancer | Q35179411 | ||
| Clinical studies with non-iressa EGFR tyrosine kinase inhibitors | Q35179418 | ||
| Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours | Q36671549 | ||
| Tumor angiogenesis: review of current applications in tumor prognostication | Q40387354 | ||
| Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. | Q40657525 | ||
| Mrp1 Multidrug Resistance‐Associated Protein and P‐Glycoprotein Expression in Rat Brain Microvessel Endothelial Cells | Q41021640 | ||
| Effects of radiotherapy and estramustine on the microvasculature in malignant glioma | Q41810033 | ||
| Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma | Q41836728 | ||
| Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. | Q42818347 | ||
| Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors | Q43907793 | ||
| ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. | Q44106085 | ||
| Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. | Q44393459 | ||
| Cytotoxic effect and uptake of estramustine in a rat glioma model | Q47760314 | ||
| Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma | Q53436731 | ||
| Angiostatin and endostatin: endothelial cell-specific endogenous inhibitors of angiogenesis and tumor growth | Q53916397 | ||
| Angiogenesis factors in gliomas: a new key to tumour therapy? | Q55472560 | ||
| VEGF and tPA Co-Expressed in Malignant Glioma | Q55478910 | ||
| Microvessel density is a prognostic indicator for patients with astroglial brain tumors. | Q55479921 | ||
| Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA) | Q67727767 | ||
| Angiostatin induces and sustains dormancy of human primary tumors in mice | Q71101907 | ||
| United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition) | Q74155605 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vandetanib | Q7914515 |
| P304 | page(s) | 1174-1180 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model | |
| P478 | volume | 91 |
| Q30300114 | A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients |
| Q36401846 | A phase I/II trial of vandetanib for patients with recurrent malignant glioma |
| Q60935363 | Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma |
| Q39341824 | Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors. |
| Q40019510 | Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model |
| Q34127138 | Experimental approaches for the treatment of malignant gliomas |
| Q48142924 | Hyperoxia retards growth and induces apoptosis, changes in vascular density and gene expression in transplanted gliomas in nude rats |
| Q33989239 | MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas |
| Q37187383 | Mechanisms of disease: temozolomide and glioblastoma--look to the future |
| Q37416895 | Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors |
| Q38106370 | Update on bevacizumab and other angiogenesis inhibitors for brain cancer |
Search more.